Please assess the completion status of the following clinical trial:

Trial Title: Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed locally advanced (irresectable) or metastatic biliary tract cancers.~2. Measurable disease. Defined as tumor that have uni or bi dimensional measurement not less than 1.5 cm on any dimension.~3. Age ≥ 18 years.~4. Signed written informed consent before enrolment.~5. No prior chemotherapy or anti-neoplastic therapy other than radiotherapy more than 4 weeks prior to enrolment and to areas other than the measurable disease.~6. Patients of either sex or child bearing age must be willing to use adequate contraceptive measures during the study and for 6 months after treatment.~7. Life expectancy of 6 months or more.~8. Eastern Cooperative Oncology Group performance status of 0-1.~9. Adequate renal function: creatinine within normal institutional range.~10. Adequate hepatic function: Total bilirubin within normal institutional limits, serum aspartate aminotransferase and alanine aminotransferase levels ≤2.5 times the institutional upper limit of normal or ≤ 5 times the institutional upper limit of normal of elevated because of liver involvement.~11. Adequate hematological values: leukocyte count ≥3.0 x 109/L, an absolute neutrophil count ≥1.5 x 109/L, a platelet count ≥100 x 109/L.~Exclusion Criteria:~1. Known or suspected dihydropyrimidine deficiency.~2. Presence of central nervous system metastasis.~3. Previous malignancy within 5 years, except adequately treated non melanomatous skin cancer or in situ cervical cancer.~4. Severe cardiovascular disease (congestive heart failure New York Heart Association class three or four, unstable angina pectoris, myocardial infarction or significant arrhythmias).~5. Psychiatric or mental disorder, precluding understanding of the information of the trial related topics and giving valid informed consent.~6. Active uncontrolled infection.~7. Pregnant patients (confirmed by β-Human chorionic gonadotrophin test where appropriate).~8. Serious underlying medical condition (in the judgement of the investigator) which could impair the ability of the patient to participate in the trial.~9. Any psychological, familial, geographic or social circumstances which could impair the patient's ability to participate in the trial and comply with follow up.~10. Treatment with other experimental drugs within 30 days of entry into the trial.~11. Treatment with other anti-cancer therapy.~12. Known hypersensitivity to any of the study drugs.~13. Breast feeding~14. Legal incapacity.~15. Patients with a known diagnosis of HIV infection.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Experimental single arm (Type: EXPERIMENTAL): Chemotherapy using the FOLFIRINOX regimen will be given every 2 weeks for a total of 12 cycles. FOLFIRINOX consist of:~1. Oxaliplatin-85 mg/m2 IV Day 1~2. Leucovorin-400 mg/m2 IV Day 1~3. Irinotecan-180 mg/m2 IV Day 1~4. Fluorouracil (FU)-400 mg/m2 IV bolus Day 1~5. Fluorouracil 2400 mg/m2 infused over 46 hours starting day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).